title: Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation.
abstract: Improvement in diagnostic cytogenetic techniques has led to the recognition of an increasing number of leukemia-associated chromosomal translocations and inversions. These genetic lesions frequently are associated with the disruption of putative transcription factors and the production of hybrid transcripts that are implicated in leukemogenesis. Epidemiologic evidence suggests that some, but not all, individuals with a history of gamma-irradiation exposure are at increased risk of developing chronic myeloid leukemia (CML). CML is characterized by the Philadelphia chromosome and transcription of the resulting hybrid BCR-ABL gene. Utilizing the leukemia-associated BCR-ABL p210 transcript as a marker, we sought differences in the induction of illegitimate genetic recombination following high-dose gamma-irradiation of karyotypically normal lymphoblastoid cell lines (LCL) derived from individuals with and without a history of myeloid leukemias. Six LCL [4 leukemia patient derived [2 acute myeloid leukemia and 2 CML] and 2 from normal individuals were analyzed with reverse transcriptase polymerase chain reaction for BCR-ABL under stringent conditions following exposure to 0, 50, or 100 Gy of LET gamma-irradiation delivered via a Varian linear accelerator at 4 MV. Transcripts identical to disease-associated b2a2 and b3a2 transcripts were detected both spontaneously (background illegitimate genetic recombination) and following gamma-irradiation. Background BCR-ABL positivity was demonstrable in 4 of the 6 LCL, with no significant difference in detection between leukemic- and nonleukemic-derived LCL. Overall, increasing gamma-irradiation dose resulted in an increased frequency of BCR-ABL transcript detection (0 Gy vs 50 Gy vs 100 Gy,p = 0.0023, Chi-square test). Within the leukemic- but not the nonleukemic-derived LCL there was significantly greater BCR-ABL positivity after gamma-irradiation compared to unirradiated equivalents. Furthermore, the BCR-ABL positivity of both the AML- and CML-derived LCL after gamma-irradiation was significantly greater than that of the nonleukemic-derived LCL after gamma-irradiation. We speculate that this difference in the detection of illegitimate after gamma-irradiation recombination may be due to aberrant DNA double strand break repair mechanisms in individuals predisposed to the development of myeloid leukemias.
authors.affiliation: Hunter Leukaemia & Lymphoma Research Group, Hunter Area Pathology Service, Mater Misericordiae Hospital, Waratah, NSW, Australia. andrew.spencer@netspace.com.au
authors.forename: A
authors.initials: A
authors.lastname: Spencer
authors.forename: N
authors.initials: N
authors.lastname: Granter
mesh_terms: D000208:Acute Disease; D000328:Adult; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000528:radiation effects; D002478:Cells, Cultured; D002877:Chromosomes, Human / Q000528:radiation effects; D004249:DNA Damage; D004260:DNA Repair; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D005720:Gamma Rays; D015973:Gene Expression Regulation, Leukemic / Q000528:radiation effects*; D016313:Genes, abl / Q000528:radiation effects; D020022:Genetic Predisposition to Disease; D006801:Humans; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000209:etiology / Q000235:genetics / Q000473:pathology; D007951:Leukemia, Myeloid / Q000209:etiology / Q000235:genetics / Q000473:pathology*; D018499:Linear Energy Transfer; D008214:Lymphocytes / Q000378:metabolism / Q000528:radiation effects*; D008875:Middle Aged; D009381:Neoplasms, Radiation-Induced / Q000209:etiology / Q000235:genetics; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000528:radiation effects; D010315:Particle Accelerators; D016133:Polymerase Chain Reaction; D011995:Recombination, Genetic / Q000528:radiation effects*; D012306:Risk; D014407:Tumor Cells, Cultured / Q000528:radiation effects
chemical_list: D016044:Fusion Proteins, bcr-abl